

**2021 Multiple Sclerosis Updates: A Focus on New and Emerging Therapies, Best Practices in Clinical Management and Key Considerations During the COVID-19 Era**  
**Tweetorial #5 References**

**Tweet 4**

Langer-Gould A, Popat RA, Huang SM, et al. Clinical and demographic predictors of long-term disability in patients with relapsing-remitting multiple sclerosis: a systematic review. *Arch Neurol*. 2006;63(12):1686-1691.

**Tweets 7 & 9**

Copaxone [full prescribing information]. Parsippany, NJ: Teva Neuroscience, Inc.; 2020.

Betaseron. [full prescribing information]. Whippany, NJ: Bayer HealthCare Pharmaceuticals Inc.; 2021.

Avonex. [full prescribing information]. Cambridge, MA: Biogen Inc.; 2020.

Plegridy [full prescribing information]. Cambridge, MA: Biogen Inc.; 2021.

Mavenclad [full prescribing information]. Rockland, MA: EMD Serono, Inc.; 2019.

Tecfidera [full prescribing information]. Cambridge, MA: Biogen Inc.; 2013.

Vumerity [full prescribing information]. Cambridge, MA: Biogen Inc.; 2021.

Bafiertam [full prescribing information]. High Point, NC: Banner Life Sciences; 2021.

Gilenya [full prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals; 2019.

Zeposia [full prescribing information]. Summit, NJ: Celgene Corporation; 2021.

Mayzent [full prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals; 2021.

Aubagio. [full prescribing information]. Cambridge, MA: Genzyme Corporation; 2021.

Lemtrada [full prescribing information]. Cambridge, MA: Genzyme Corporation; 2021.

Ocrevus [full prescribing information]. San Francisco, CA: Genentech, Inc.; 2021.

Tsybari [full prescribing information]. Cambridge, MA: Biogen Inc.; 2020.

Kesimpta [full prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals; 2020.

**Tweet 11**

Naismith RT, Wundes A, Ziemssen T, et al. diroximel fumarate demonstrates an improved gastrointestinal tolerability profile compared with dimethyl fumarate in patients with relapsing-remitting multiple sclerosis: results from the randomized, double-blind, phase III EVOLVE-MS-2 study. *CNS Drugs*. 2020;34(2):185-196.

**Tweet 12**

Rieckmann P, Boyko A, Centonze D, et al. Achieving patient engagement in multiple sclerosis: A perspective from the multiple sclerosis in the 21st Century Steering Group. *Mult Scler Relat Disord*. 2015;4(3):202-218.

**Tweet 13**

International Organization of Multiple Sclerosis Nurses. Clinical practice guidelines. Accessed October 12, 2021. <http://iomsn.org/clinical-practice-guidelines>

## Glossary

AC, acromioclavicular joint  
AfrAm, African American  
AE, adverse event  
BID, twice a day  
CI, confidence interval  
D, day  
DMF, dimethyl fumarate  
DMT, disease-modifying therapy  
DRF, diroximel fumarate  
Dx, diagnosis  
Dz, disease  
FT, full-time  
GA, glatiramer acetate  
Gd, gadolinium  
GGISIS, Global GI Symptom and Impact Scale  
GI, gastrointestinal  
H, hour  
Hx, history  
IGISIS, Individual GI Symptoms and Impact Scale  
IFN, interferon  
IM, intramuscular  
IV, intravenous  
M, month  
Maint, maintenance  
Mgmt, management  
MS, multiple sclerosis  
Nav, navigate  
PO, by mouth  
PRO, patient reported outcomes  
Pt(s), patient(s)  
Q4W, every four weeks  
Q6W, every six weeks  
QD, every day  
QM, every month  
QoL, quality of life  
QW, every week  
RMS, relapsing forms of multiple sclerosis  
RR, rate ratio  
S1PR, sphingosine-1-phosphate receptor  
SC, subcutaneous  
TIW, three times a week  
Tx, treatment  
WK, week  
Y, year  
YO, years old